Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1699 | Health warning leaflet Wiki | 1.00 |
| drug162 | AWARD plus COVID-specific advice Wiki | 1.00 |
| drug3481 | SMS-based support Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The present study will examine (1) the effectiveness of a combined brief advice and personalized chat-based support on COVID-19 related smoking messages and (2) explore the use of CBPR model to build capacity and to engage community partners in taking on this important public health issue for sustainability in the community. In addition, a process evaluation will be conducted to assess the effectiveness of the recruitment activity and how it is linked with the overall program outcomes.
Description: The primary outcomes are biochemically validated quit rates (exhaled CO < 4 ppm and salivary cotinine < 30 ng/ml) at 3-month in the two groups
Measure: Biochemical validated quit rate Time: 3-month follow-upDescription: The primary outcomes are biochemically validated quit rates (exhaled CO < 4 ppm and salivary cotinine < 30 ng/ml) at 6-month in the two groups
Measure: Biochemical validated quit rate Time: 6-month follow-upDescription: Self-reported 7-day point prevalence (pp) quit rate at 3-month between the two groups
Measure: Smoking quit rate change from baseline at 3-month follow-up Time: 3-month follow-upDescription: Self-reported 7-day point prevalence (pp) quit rate at 6-month between the two groups
Measure: Smoking quit rate change from baseline at 6-month follow-up Time: 6-month follow-upDescription: Rate of smoking reduction by at least half of baseline amount in the two groups
Measure: Smoking reduction rate change from baseline at 3-month follow-up Time: 3-month follow-upDescription: Rate of smoking reduction by at least half of baseline amount in the two groups
Measure: Smoking reduction rate change from baseline at 6-month follow-up Time: 6-month follow-upDescription: Number of quit attempts at 3-month in the two groups
Measure: Smoking quit attempt change from baseline at 3-month follow-up Time: 3-month follow-upDescription: Number of quit attempts at 6-month in the two groups
Measure: Smoking quit attempt change from baseline at 6-month follow-up Time: 6-month follow-upDescription: Use of smoking cessation at 3 and 6 month follow-up in the two groups
Measure: Use of smoking cessation service Time: 3 and 6 months follow-upDescription: Self-reported engagement in chat-based/SMS-based support in the two groups
Measure: Engagement in chat-based/SMS-based support Time: 3 and 6 months follow-upAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports